1. In this cohort study, dulaglutide, semaglutide, and tirzepatide demonstrated similar risks of gastrointestinal adverse events (AEs) in adults with ...
1. In patients with type 2 diabetes (T2D), the risk of major adverse cardiovascular events (MACEs) was lowest among patients ...
Click here to read this study in NEJM. ©2025 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced ...
1. In this population-based cohort study, patients with type 2 diabetes who received glucagon-like peptide-1 receptor agonists had a higher ...
Click here to read this study in NEJM. ©2025 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced ...
1. In this retrospective cohort study, treatment with semaglutide resulted in nominally lower incidence of the composite of death, myocardial ...
1. Maximum walking distance at 52 weeks was significantly improved with semaglutide. 2. There were fewer treatment-related serious adverse events ...
1. In this retrospective cohort study, tirzepatide dispensations were found to have increased significantly following approval in the United States ...
1. In this target trial emulation, glucagon-like peptide-1 receptor agonists (GLP-1RAs) were associated with a lower risk of depression compared ...
1. In this multi-database retrospective cohort study, rosuvastatin was found to be associated with slightly decreased risk of all-cause mortality ...
